Our findings suggested that targeting EphA4 may lead to a novel inhibiting effect combined with other regulators in breast cancer therapy, especially where the tumor cell proliferation and survival are dependent on local tissue IGF1 production. Here, IGF1 is linked to breast carcinoma.